MX2021006156A - Compuestos utiles en la terapia para el vih. - Google Patents
Compuestos utiles en la terapia para el vih.Info
- Publication number
- MX2021006156A MX2021006156A MX2021006156A MX2021006156A MX2021006156A MX 2021006156 A MX2021006156 A MX 2021006156A MX 2021006156 A MX2021006156 A MX 2021006156A MX 2021006156 A MX2021006156 A MX 2021006156A MX 2021006156 A MX2021006156 A MX 2021006156A
- Authority
- MX
- Mexico
- Prior art keywords
- compounds useful
- hiv therapy
- compounds
- hiv
- therapy
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/554—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one sulfur as ring hetero atoms, e.g. clothiapine, diltiazem
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Virology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Molecular Biology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Tropical Medicine & Parasitology (AREA)
- AIDS & HIV (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
- Steroid Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Abstract
La invención se refiere a compuestos de fórmula (I), (Ia), (Ib), (II) o (III), sales de los mismos, a composiciones farmacéuticas de los mismos, así como a procedimientos terapéuticos de tratamiento y prevención.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201862773563P | 2018-11-30 | 2018-11-30 | |
PCT/IB2019/060267 WO2020110056A1 (en) | 2018-11-30 | 2019-11-28 | Compounds useful in hiv therapy |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2021006156A true MX2021006156A (es) | 2021-09-08 |
Family
ID=68808475
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2021006156A MX2021006156A (es) | 2018-11-30 | 2019-11-28 | Compuestos utiles en la terapia para el vih. |
MX2023014492A MX2023014492A (es) | 2018-11-30 | 2021-05-26 | Compuestos utiles en la terapia para el vih. |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2023014492A MX2023014492A (es) | 2018-11-30 | 2021-05-26 | Compuestos utiles en la terapia para el vih. |
Country Status (15)
Country | Link |
---|---|
EP (2) | EP3886987B1 (es) |
JP (2) | JP7406556B2 (es) |
KR (1) | KR20210097154A (es) |
CN (1) | CN113613724A (es) |
AR (1) | AR117206A1 (es) |
AU (1) | AU2019390729B2 (es) |
BR (1) | BR112021010353A2 (es) |
CA (1) | CA3121140A1 (es) |
CL (1) | CL2021001388A1 (es) |
ES (1) | ES2968538T3 (es) |
IL (2) | IL310831A (es) |
MX (2) | MX2021006156A (es) |
TW (1) | TWI824069B (es) |
WO (1) | WO2020110056A1 (es) |
ZA (1) | ZA202103349B (es) |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11466017B2 (en) | 2011-03-10 | 2022-10-11 | Board Of Regents, The University Of Texas System | Heterocyclic inhibitors of PTPN11 |
AU2017274199B2 (en) | 2016-05-31 | 2021-09-23 | Board Of Regents, The University Of Texas System | Heterocyclic inhibitors of PTPN11 |
WO2019213318A1 (en) | 2018-05-02 | 2019-11-07 | Board Of Regents, The University Of Texas System | Substituted heterocyclic inhibitors of ptpn11 |
JP2021534124A (ja) | 2018-08-10 | 2021-12-09 | ナビール ファーマ,インコーポレイティド | 癌治療用ptpn11(shp2)阻害剤としての6−(4−アミノ−3−メチル−2−オキサ−8−アザスピロ[4.5]デカン−8−イル)−3−(2,3−ジクロロフェニル)−2−メチルピリミジン−4(3h)−オン誘導体及び関連化合物 |
TW202039426A (zh) | 2018-11-30 | 2020-11-01 | 美商彗星製藥公司 | 泛硫醇(Pantetheine)衍生物及其用途 |
CA3160666A1 (en) * | 2019-11-08 | 2021-05-14 | Sanford Burnham Prebys Medical Discovery Institute | Inhibitor of apoptosis (iap) protein antagonists |
US20240173276A1 (en) * | 2021-03-23 | 2024-05-30 | The University Of North Carolina At Chapel Hill | Methods and compositions for inhibiting formation of the hiv latent reservoir |
Family Cites Families (38)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB427857A (en) | 1934-08-02 | 1935-05-01 | Newsum Sons & Company Ltd H | A new or improved system of construction for skeleton structures, particularly vehicle body frames and door frames |
US4107288A (en) | 1974-09-18 | 1978-08-15 | Pharmaceutical Society Of Victoria | Injectable compositions, nanoparticles useful therein, and process of manufacturing same |
US5145684A (en) | 1991-01-25 | 1992-09-08 | Sterling Drug Inc. | Surface modified drug nanoparticles |
US5681835A (en) | 1994-04-25 | 1997-10-28 | Glaxo Wellcome Inc. | Non-steroidal ligands for the estrogen receptor |
GB9716557D0 (en) | 1997-08-06 | 1997-10-08 | Glaxo Group Ltd | Benzylidene-1,3-dihydro-indol-2-one derivatives having anti-cancer activity |
US7605238B2 (en) | 1999-08-24 | 2009-10-20 | Medarex, Inc. | Human CTLA-4 antibodies and their uses |
KR100942863B1 (ko) | 1999-08-24 | 2010-02-17 | 메다렉스, 인코포레이티드 | 인간 씨티엘에이-4 항체 및 그의 용도 |
MXPA03005696A (es) | 2000-12-21 | 2003-10-06 | Glaxo Group Ltd | Pirimidinaminas como moduladores de angiogenesis. |
HUP0400241A2 (hu) | 2001-03-19 | 2004-06-28 | Ono Pharmaceutical Co., Ltd. | Hatóanyagként triaza-spiro[5.5]undekán-származékokat tartalmazó gyógyszerkészítmények |
AU2003281200A1 (en) | 2002-07-03 | 2004-01-23 | Tasuku Honjo | Immunopotentiating compositions |
CA2508660C (en) | 2002-12-23 | 2013-08-20 | Wyeth | Antibodies against pd-1 and uses therefor |
EP2270051B1 (en) | 2003-01-23 | 2019-05-15 | Ono Pharmaceutical Co., Ltd. | Antibody specific for human PD-1 and CD3 |
US7378423B2 (en) | 2004-06-11 | 2008-05-27 | Japan Tobacco Inc. | Pyrimidine compound and medical use thereof |
SI1761528T1 (sl) | 2004-06-11 | 2008-06-30 | Japan Tobacco Inc | 5-amino-2,4,7-triokso-3,4,7,8-tetrahidro-2H-pirido(2,3-D)pirimidinski derivati in sorodne spojine za zdravljenje raka |
NZ563193A (en) | 2005-05-09 | 2010-05-28 | Ono Pharmaceutical Co | Human monoclonal antibodies to programmed death 1(PD-1) and methods for treating cancer using anti-PD-1 antibodies alone or in combination with other immunotherapeutics |
SI1907424T1 (sl) | 2005-07-01 | 2015-12-31 | E. R. Squibb & Sons, L.L.C. | Humana monoklonska protitelesa proti programiranem smrtnem ligandu 1 (PD-L1) |
EP2019671B1 (en) | 2006-05-05 | 2014-09-24 | The Regents Of The University Of Michigan | Intermediates for the preparation of bivalent smac mimetics |
CN201013021Y (zh) | 2006-11-24 | 2008-01-30 | 李一君 | 排水器改进结构 |
UY30892A1 (es) | 2007-02-07 | 2008-09-02 | Smithkline Beckman Corp | Inhibidores de la actividad akt |
ES2437327T3 (es) | 2007-06-18 | 2014-01-10 | Merck Sharp & Dohme B.V. | Anticuerpos para el receptor PD-1 humano de muerte programada |
EP2058312A1 (en) * | 2007-11-09 | 2009-05-13 | Universita' degli Studi di Milano | SMAC mimetic compounds as apoptosis inducers |
EP2262837A4 (en) | 2008-03-12 | 2011-04-06 | Merck Sharp & Dohme | PD-1 BINDING PROTEINS |
US20110159023A1 (en) | 2008-08-25 | 2011-06-30 | Solomon Langermann | Pd-1 antagonists and methods for treating infectious disease |
SI2342226T1 (sl) | 2008-09-26 | 2016-11-30 | Dana-Farber Cancer Institute Inc. | Humana protitelesa proti PD-1, PD-L1 in PD-L2 in njihove uporabe |
CN114835812A (zh) | 2008-12-09 | 2022-08-02 | 霍夫曼-拉罗奇有限公司 | 抗-pd-l1抗体及它们用于增强t细胞功能的用途 |
US20100317593A1 (en) * | 2009-06-12 | 2010-12-16 | Astrazeneca Ab | 2,3-dihydro-1h-indene compounds |
ES2643233T3 (es) * | 2009-10-23 | 2017-11-21 | The Regents Of The University Of Michigan | Miméticos de SMAC bicíclicos diazo bivalentes y los usos de los mismos |
JP5529282B2 (ja) * | 2009-10-28 | 2014-06-25 | ジョイアント ファーマスーティカルズ、インク. | 二量体Smac模倣薬 |
CA2992770A1 (en) | 2009-11-24 | 2011-06-03 | Medimmune Limited | Targeted binding agents against b7-h1 |
JP2013512251A (ja) | 2009-11-24 | 2013-04-11 | アンプリミューン、インコーポレーテッド | Pd−l1/pd−l2の同時阻害 |
US20110280877A1 (en) | 2010-05-11 | 2011-11-17 | Koji Tamada | Inhibition of B7-H1/CD80 interaction and uses thereof |
BR112014002353B1 (pt) | 2011-08-01 | 2022-09-27 | Genentech, Inc | Usos de antagonistas de ligação do eixo pd-1 e inibidores de mek, composições farmacêuticas, e kit |
EA036814B9 (ru) | 2011-11-28 | 2021-12-27 | Мерк Патент Гмбх | Антитело против pd-l1 (варианты), композиция, содержащая это антитело, и их применение |
SG11201407190TA (en) | 2012-05-15 | 2014-12-30 | Bristol Myers Squibb Co | Cancer immunotherapy by disrupting pd-1/pd-l1 signaling |
MX370848B (es) | 2012-10-04 | 2020-01-08 | Dana Farber Cancer Inst Inc | Anticuerpos monoclonales humanos anti-pd-l1 y métodos de uso. |
EP2925764B1 (en) * | 2012-11-30 | 2023-03-01 | Sanford-Burnham Medical Research Institute | Inhibitor of apoptosis protein (iap) antagonists |
JP6768522B2 (ja) * | 2014-06-04 | 2020-10-14 | サンフォード−バーンハム メディカル リサーチ インスティテュート | Hiv治療におけるアポトーシスタンパク質阻害剤(iap)のアンタゴニストの使用 |
CA3160666A1 (en) * | 2019-11-08 | 2021-05-14 | Sanford Burnham Prebys Medical Discovery Institute | Inhibitor of apoptosis (iap) protein antagonists |
-
2019
- 2019-11-28 EP EP19816924.5A patent/EP3886987B1/en active Active
- 2019-11-28 BR BR112021010353-8A patent/BR112021010353A2/pt unknown
- 2019-11-28 AR ARP190103484A patent/AR117206A1/es unknown
- 2019-11-28 KR KR1020217019819A patent/KR20210097154A/ko active Search and Examination
- 2019-11-28 IL IL310831A patent/IL310831A/en unknown
- 2019-11-28 AU AU2019390729A patent/AU2019390729B2/en active Active
- 2019-11-28 JP JP2021531316A patent/JP7406556B2/ja active Active
- 2019-11-28 CA CA3121140A patent/CA3121140A1/en active Pending
- 2019-11-28 WO PCT/IB2019/060267 patent/WO2020110056A1/en active Application Filing
- 2019-11-28 EP EP23206927.8A patent/EP4342473A3/en active Pending
- 2019-11-28 CN CN201980090907.2A patent/CN113613724A/zh active Pending
- 2019-11-28 TW TW108143509A patent/TWI824069B/zh active
- 2019-11-28 ES ES19816924T patent/ES2968538T3/es active Active
- 2019-11-28 IL IL283487A patent/IL283487B2/en unknown
- 2019-11-28 MX MX2021006156A patent/MX2021006156A/es unknown
-
2021
- 2021-05-18 ZA ZA2021/03349A patent/ZA202103349B/en unknown
- 2021-05-26 MX MX2023014492A patent/MX2023014492A/es unknown
- 2021-05-27 CL CL2021001388A patent/CL2021001388A1/es unknown
-
2023
- 2023-11-09 JP JP2023191205A patent/JP2024023259A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
EP3886987A1 (en) | 2021-10-06 |
IL283487A (en) | 2021-07-29 |
JP7406556B2 (ja) | 2023-12-27 |
TW202039514A (zh) | 2020-11-01 |
AR117206A1 (es) | 2021-07-21 |
WO2020110056A1 (en) | 2020-06-04 |
TWI824069B (zh) | 2023-12-01 |
BR112021010353A2 (pt) | 2021-08-31 |
CL2021001388A1 (es) | 2021-11-05 |
CA3121140A1 (en) | 2020-06-04 |
JP2022509869A (ja) | 2022-01-24 |
EP3886987C0 (en) | 2023-11-15 |
EP3886987B1 (en) | 2023-11-15 |
IL283487B1 (en) | 2024-03-01 |
EP4342473A2 (en) | 2024-03-27 |
ZA202103349B (en) | 2022-12-21 |
KR20210097154A (ko) | 2021-08-06 |
AU2019390729A1 (en) | 2021-06-03 |
IL310831A (en) | 2024-04-01 |
EP4342473A3 (en) | 2024-05-15 |
IL283487B2 (en) | 2024-07-01 |
CN113613724A (zh) | 2021-11-05 |
JP2024023259A (ja) | 2024-02-21 |
ES2968538T3 (es) | 2024-05-10 |
MX2023014492A (es) | 2024-01-25 |
AU2019390729B2 (en) | 2022-08-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2023014492A (es) | Compuestos utiles en la terapia para el vih. | |
PH12018502489A1 (en) | Antiviral therapy | |
MD4800C1 (ro) | Compuşi de aminopirimidinil ca inhibitori de JAK | |
NZ733174A (en) | Quinazoline derivatives used to treat hiv | |
EA201891063A1 (ru) | Производные дигидроимидазопиразинона, применимые в лечении рака | |
PH12018502077A1 (en) | Substituted indoline derivatives as dengue viral replication inhibitors | |
PH12016502355A1 (en) | Pharmaceutical composition | |
MX2018011788A (es) | Derivados de indolina sustituidos como inhibidores de la replicacion virica de dengue. | |
PH12016502353A1 (en) | Pharmaceutical composition | |
CR20210460A (es) | Compuestos útiles en la terapia del vih | |
PH12016502352A1 (en) | Pharmaceutical composition | |
MX2021001612A (es) | Compuestos utiles en terapia del vih. | |
PH12019500568A1 (en) | Dopamine-b-hydroxylase inhibitors | |
MX2019012522A (es) | Compuestos y metodos terapeuticos. | |
MX2020010552A (es) | Derivados de bumetanida para el tratamiento de la hiperhidrosis. | |
PH12020500542A1 (en) | Dopamine-b-hydroxylase inhibitors | |
WO2019028309A1 (en) | AZAINDOLES AND THEIR METHODS OF USE | |
EA201600411A1 (ru) | Производные пиперидина для применения при лечении или профилактики психиатрических и неврологических состояний |